Back to today’s briefing

Story perspectives

Insmed's Brinsupri Approved: First Treatment for Bronchiectasis

8/13/2025

22 5

Summary

Story summary

Insmed Inc. has made a groundbreaking leap with FDA approval for Brinsupri (brensocatib), the first-ever treatment for non-cystic fibrosis bronchiectasis, set to hit the market in Q3 2025. With over 1.25 million potential patients, analysts foresee U.S. sales soaring to $500–700 million, propelling Insmed's ambitious global expansion in the biotech arena.

1 of 1

Story summary

Insmed Inc. has made a groundbreaking leap with FDA approval for Brinsupri (brensocatib), the first-ever treatment for non-cystic fibrosis bronchiectasis, set to hit the market in Q3 2025. With over 1.25 million potential patients, analysts foresee U.S. sales soaring to $500–700 million, propelling Insmed's ambitious global expansion in the biotech arena.